AstraZeneca share price: is this FTSE 100 growth stock now a top ‘dip buy’?

The AstraZeneca share price has underperformed the FTSE 100 in recent months. G A Chester weighs up its dip-buy credentials.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE: AZN) share price has smashed the FTSE 100 over one, three, five and 10 years. However, this blue-chip growth stock has underperformed more recently. On a six-month view, it’s down 14%, compared with a 10% rise in the index.

Is AstraZeneca a top ‘dip buy’ for me today, and should I jump at the chance to invest at the current share price?

Key changes

I’ve been wary of AstraZeneca’s valuation in recent years. Indeed, when I last covered the stock (May last year), I rated it a ‘sell’. At a share price of 9,004p, I calculated its valuation as somewhere between far too rich and grossly overvalued.

However, for me, two key things have changed. First, the AstraZeneca share price is now 20% lower at 7,226p. And second, the company has recently issued its latest annual report. This has enabled me to reassess a feature of AZN’s earnings that I previously felt had been flattering its performance.

AstraZeneca’s shares priced on ‘core’ numbers

AstraZeneca gives investors an idea of the underlying financial performance of the business using what it calls ‘core’ numbers. I’m okay with most of the adjustments the company makes to its statutory results to arrive at its core numbers. However, I take issue with one.

AZN books one-off gains from disposing of non-core drugs as core operating profit. In my view, this doesn’t accurately reflect the underlying performance of the ongoing business. It flatters it.

By 2018, such disposals accounted for £1.9bn (a full third) of AZN’s £5.7bn core operating profit. I was encouraged to see this moderate to around a fifth in 2019. And following the recent 2020 results, the table below brings the position up to date.

 

2014

2015

2016

2017

2018

2019

2020

Statutory operating profit ($bn)

2.1

4.1

4.9

3.7

3.4

2.9

5.2

Adjustments (before gains on disposals) (£bn)

4.8

1.8

0.5

1.7

0.4

2.3

1.1

My core operating profit (£bn)

6.9

5.9

5.4

5.3

3.8

5.2

6.3

Gains on disposals (£bn)

0.0

1.0

1.3

1.5

1.9

1.2

1.0

AZN core operating profit (£bn)

6.9

6.9

6.7

6.8

5.7

6.4

7.3

Gains on disposals as % of AZN core operating profit

0

14

19

22

33

19

14

I’m further encouraged to see another reduction (down to 14%) in the contribution of gains on disposals in 2020. I think AZN’s core numbers are beginning to better reflect the underlying performance of the ongoing business.

AstraZeneca share price and valuation

How has the change in AstraZeneca’s share price and publication of its latest annual results affected the valuation of the stock since I last wrote about it?

 

P/E May 2020

P/E today

Statutory

107

42

My core

40

32

AZN core

31

26

The fall in AstraZeneca’s share price and an increase in its earnings at growth-stock rates (mid/high teens on both my and AZN’s numbers) have made the price-to-earnings (P/E) ratios much more appealing today. Furthermore, they become more attractive still looking forward. Management has guided on earnings growth of between 18% and 24% for 2021.

Risk and reward

Of course, there’s a risk the company’s impressive line-up of new medicines may not deliver the level of growth management, analysts and the market are currently expecting. In which case, the AstraZeneca share price could de-rate further.

In addition, there’s a risk that wasn’t present when I covered the stock last year. The company is set to buy US group Alexion Pharmaceuticals in a $39bn deal. Such mega-acquisitions are complex and don’t always create the new shareholder value management anticipates.

On balance though, weighing my personal appetite for risk and reward, I am looking at today’s AstraZeneca share price as a top FTSE 100 ‘dip buy’ opportunity.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »